About Titan Pharma
Titan Pharma is a publicly listed company based in San Francisco (United States) founded in 1992. A specialty pharmaceutical company developing proprietary therapeutics for select chronic diseases. Titan Pharma offers products and services including Research Services and Investor Presentations. Its focus areas include Life Sciences, Neurology, Drugs and Psychiatric. Its legal entity is Titan Pharmaceuticals, Inc. Its competitors include Indivior, Braeburn and Cessation Therapeutics; 2 of its 3 listed competitors have raised funding.
Company details
Titan Pharma was founded in 1992 in San Francisco, United States, as a specialty pharmaceutical company. Therapeutics for select chronic diseases are developed through the ProNeura platform, which enables long-term, continuous drug delivery. The lead candidate, Probuphine, consists of a six-month buprenorphine implant for opioid addiction maintenance; an FDA action date was set for May 27, 2016. Preclinical programs include ropinirole implants for Parkinsons disease and T3 implants for hypothyroidism.
- Headquarters San Francisco, United States
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website titanpharm.com
- Social X
- Legal Name Titan Pharmaceuticals, Inc.
- Net Profit-$2.48 M (USD)47.2as on Dec 31, 2025
- EBITDA-$2.42 M (USD)46.95as on Dec 31, 2025
- Latest Funding Round$600K (USD), Post-IPO
Jun 2025
- InvestorsGates Foundation
& 3 more
Products & Services of Titan Pharma
Titan Pharma offers a comprehensive portfolio of products and services, including Research Services and Investor Presentations.
Offers pharmaceutical research for health advancements
Provides data on company performance and filings
Funding Insights of Titan Pharma
- Total Rounds 11
- Last Round Post-IPO — $600,000
- First Round $7.59M
(Sep 2009)
- Investors Count 4
Latest 10 of 11 funding rounds of Titan Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2025 | $600,000 | Post-IPO | – | – | – |
| Feb 2022 | $1.52M | Post-IPO | – | – | – |
| Oct 2021 | Grant | – | – | ||
| Jan 2021 | $9.67M | Post-IPO | – | – | – |
| Jan 2020 | $2.18M | Post-IPO | – | – | – |
| Sep 2019 | $6.1M | Grant | – | – | |
| Jun 2018 | $2.7M | Grant | – | – | |
| Jul 2017 | $7M | Debt – Venture | – | – | |
| Aug 2010 | $495,000 | Grant | – | – | |
| Jul 2010 | $495,000 | Grant | – | – |
4 investors in total: 4 institutional.
Investors in Titan Pharma
Titan Pharma has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation, HHS and Horizon Tech Finance.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Structured debt is provided to life sciences and technology firms. | 2004 | horizontechfinance.com | Farmington, United States | |
Charitable foundation investments on poverty reduction and healthcare | 2000 | gatesfoundation.org | Seattle, United States | |
Scientific research on drug use and addiction is supported. | drugabuse.gov | United States | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Titan Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Titan Pharma
9 people are tracked at Titan Pharma (1 in leadership, 8 in board & advisors).
| Name | Role | Group |
|---|---|---|
David E. Lazar | Interim Chairman & CEO | Leadership |
James R. McNab | Director | Board & advisors |
M. David MacFarlane | Director | Board & advisors |
Joseph A. Akers | Director | Board & advisors |
David Natan | Director | Board & advisors |
Matthew C. McMurdo | Director | Board & advisors |
Eric Greenberg | Director | Board & advisors |
Peter L. Chasey | Director | Board & advisors |
Avraham Ben-Tzvi | Director | Board & advisors |
Complete people profiles for Titan Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Titan Pharma
Titan Pharma is a publicly listed company on the NASDAQ with ticker symbol TTNP in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date18 Jan 1996
- Listed onNASDAQ: TTNP
- Listed entityTitan Pharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINKYG1156E1026
- Share price$4.15 (+2.98% on the day) · 2025-09-29
- Market capitalisation$5.5M
- EPS (diluted, trailing year)$-2.96
- Volume (last session)8,547
- Analyst consensusNeutral
Financials of Titan Pharma
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$2.5M | -$2.4M | |
| 2024 | -$4.7M | -$4.5M | |
| 2023 | $184,000 | -$5.6M | -$7.2M |
| 2022 | $557,000 | -$10.2M | -$10.0M |
| 2021 | $1.5M | -$8.8M | -$9.1M |
Detailed financial statements for Titan Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Titan Pharma
4 dated milestones of Titan Pharma across 33 years, from founding to its latest funding, stage changes and deals.
- Founded Titan Pharma is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $7.6M.
- Funding Latest funding round, Post-IPO, of $600K.
Competitors of Titan Pharma
Titan Pharma has 3 listed competitors in our database, 2 of them funded. They include Indivior, Braeburn and Cessation Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| indivior.com | 2014 | Richmond Hill, United States | 1,051 | Therapeutics for opioid addiction treatment are developed and commercialized. | ||
| braeburnrx.com | 2012 | Philadelphia, United States | $110M | Long-acting therapies for opioid addiction and chronic pain are developed. | ||
| cessationtherapeutics.com | 2017 | San Jose, United States | $6.76M | Developer of immunotherapy based vaccines to manage addictions |
Detailed competitors of Titan Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Titan Pharma
The website of Titan Pharma (titanpharm.com) receives about 4.3K visits a month and ranks #4,063,501 among all websites worldwide, #5,091 in Biotechnology and Pharmaceuticals.
- Monthly visits4.3K
- Unique visitors2K
per month
- Global rank#4,063,501
among all websites
- Category rank#5,091
Health · Biotechnology and Pharmaceuticals
- Bounce rate51%
- Pages per visit1.9
- Average visit32 sec
- DevicesDesktop 23% · Mobile 77%
Websites whose visitors overlap most with Titan Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| corvuspharma.com | 100% | 13.6K | #3,366,661 | View details | |
| eurekatherapeutics.com | 100% | 1.7K | #7,320,910 | View details | |
| astellasgenetherapies.com | 99% | 1K | View details | ||
| mbcbiolabs.com | 98% | #2,013,343 | View details | ||
| aligos.com | 97% | 3.4K | #3,982,602 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Titan Pharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as Titan Pharma (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Titan Pharma
Complete news archive for Titan Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Titan Pharma
Titan Pharma was founded in 1992 and raised its 1st funding round 17 years after it was founded.
Titan Pharma is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Titan Pharma was founded in 1992 in San Francisco, United States, as a specialty pharmaceutical company. Therapeutics for select chronic diseases are developed through the ProNeura platform, which enables long-term, continuous drug delivery. The lead candidate, Probuphine, consists of a six-month buprenorphine implant for opioid addiction maintenance; an FDA action date was set for May 27, 2016. Preclinical programs include ropinirole implants for Parkinsons disease and T3 implants for hypothyroidism.
Titan Pharma's top competitors include Indivior, Cessation Therapeutics and Braeburn.
Titan Pharma offers Research Services and Investor Presentations.
Yes, Titan Pharma is publicly traded on NASDAQ under the ticker symbol TTNP.
Titan Pharma has 4 investors. Key investors include Gates Foundation, HHS, Horizon Tech Finance, and National Institute on Drug Abuse.
Titan Pharma operates through Titan Pharmaceuticals, Inc..